GlassScriptPhysician profile
Ralph P Riley
NPI 1699800060
$980.99
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $260 · 2022: $306 · 2023: $251 · 2024: $42.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $383.29 | 2021-2023 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $246.54 | 2021-2023 | Ingrezza |
| Zimmer Biomet Holdings, INC. | $121.64 | 2020 | |
| Alkermes, INC. | $72.21 | 2022-2023 | Aristada, Vivitrol, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $41.72 | 2023-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $24.52 | 2023 | Invega Sustenna |
| Biocryst US Sales Co., LLC | $19.44 | 2024 | Orladeyo |
| Otsuka America Pharmaceutical, INC. | $18.54 | 2022 | |
| Novo Nordisk INC | $14.03 | 2021 | |
| Noven Therapeutics, LLC | $13.91 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.04 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.